Avila Santiago, Smani Danyal A, Koay Eugene J
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Chin Clin Oncol. 2020 Feb;9(1):10. doi: 10.21037/cco.2019.12.05. Epub 2019 Dec 19.
Intrahepatic cholangiocarcinoma (IHCC) and extrahepatic cholangiocarcinoma (EHCC) remain challenging diseases to treat. The majority of patients present with advanced disease, and the tumors often cause life-threatening biliary obstruction and vascular compromise of the liver. Local control (LC) of these tumors has the potential to prolong life for patients. While escalated-dose radiation therapy (EDRT) has been demonstrated to be an effective, safe option to achieve LC of IHCC, data for EHCC suggest that EDRT with current techniques has limitations, often due to dose-limiting bowel structures in close proximity to the extrahepatic biliary system. Here we review the results of EDRT for IHCC and EHCC and point to potential directions to combine radiotherapy with novel agents. The molecular characterization of cholangiocarcinoma has particularly opened new avenues for clinical investigations of targeted therapies with EDRT and may point to ways to achieve both systemic and LC benefits for patients.
肝内胆管癌(IHCC)和肝外胆管癌(EHCC)仍然是治疗上具有挑战性的疾病。大多数患者就诊时已处于疾病晚期,肿瘤常导致危及生命的胆道梗阻和肝脏血管受累。对这些肿瘤进行局部控制(LC)有可能延长患者的生命。虽然高剂量放射治疗(EDRT)已被证明是实现IHCC局部控制的一种有效、安全的选择,但关于EHCC的数据表明,采用当前技术的EDRT存在局限性,这通常是由于肝外胆道系统附近存在剂量限制的肠道结构。在此,我们回顾了EDRT治疗IHCC和EHCC的结果,并指出将放疗与新型药物联合应用的潜在方向。胆管癌的分子特征尤其为EDRT靶向治疗的临床研究开辟了新途径,并可能为实现患者全身和局部控制获益指明方向。